In 2004, a tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR) was reported to induce a dramatic tumor response compared with conventional chemotherapy in patients with NSCLC [2]. The gene discussed is EGFR; the disease is neoplasm.